ライフサイエンスコーパス: interleukin-2 receptor

1 anti-CD14, anti-HLA-DR, anti-CD54, and anti-interleukin 2 receptor.

2 body directed against the alpha chain of the interleukin 2 receptor.

3 activated cells expressing the high-affinity interleukin 2 receptor.

4 is directed against the alpha subunit of the interleukin 2 receptor.

5 -activated T cells express the high-affinity interleukin-2 receptor.

6 FR, VEGFR, PDGFR, NGFR and IGF1R, as well as interleukin-2 receptor.

7 ed the internalization of the complex spCD25-interleukin-2 receptor.

8 sor-cytotoxic, and natural killer cells) and interleukin 2 receptors.

9 , and serum samples were assayed for soluble interleukin-2 receptors.

10 or and also interacts with the CD4, CD8, and interleukin-2 receptors.

11 , or a combination (29/37), elevated soluble interleukin 2 receptor (20/21), and elevated VEGF (16/20

12 in the expression of CD25, the low-affinity interleukin 2 receptor (34% +/- 15% versus 40% +/- 16%).

13 r burden and the presence of soluble (serum) interleukin-2 receptor, a marker associated with a subse

14 ent clinical evidence for the Treg-selective interleukin-2 receptor agonist rezpegaldesleukin (REZPEG

15 Injection of anti-interleukin 2 receptor alpha (anti-IL-2Ralpha) MAb to de

16 nistered intravenously (i.v.) to bind to the interleukin 2 receptor alpha (IL-2R alpha; CD25)-express

17 the type 1 diabetes (T1D) association in the interleukin 2 receptor alpha (IL2RA) gene region to two

18 The interleukin 2 receptor alpha (IL2Ralpha; CD25; Tac) is t

19 serum with the soluble alpha subunit of the interleukin 2 receptor alpha (sIL-2R alpha).

20 te (gamma interferon [IFN-gamma] and soluble interleukin 2 receptor alpha [sIL-2Ralpha]) and adaptive

21 co-expressing a chimeric receptor containing interleukin 2 receptor alpha and GP Ibalpha cytoplasmic

22 T-MMP), nor a chimeric MT-MMP containing the interleukin 2 receptor alpha chain (IL-2R) TM and cytopl

23 The interleukin 2 receptor alpha chain (IL-2Ralpha) is a com

24 reased expression of the CD25 marker and the interleukin 2 receptor alpha chain and perturbation of C

25 le-negative CD4-8- thymocytes expressing the interleukin 2 receptor alpha chain, CD25, was also obser

26 stocompatibility complex class I (MHCI), and interleukin 2 receptor alpha subunit (Tac) was compared

27 that transmembrane secretory cargos, such as interleukin 2 receptor alpha subunit or Tac, transferrin

28 When fused to CD4 or IL2RA (interleukin 2 receptor alpha subunit) proteins, which ar

29 h humanized anti-Tac (HAT) directed to CD25 (interleukin 2 receptor alpha) or with MEDI-507 directed

30 le tumor necrosis factor receptor 2, soluble interleukin 2 receptor alpha, soluble gp130, soluble CD2

31 in the absence of CD4(+) T cells express the interleukin 2 receptor alpha-chain (CD25) at lower level

32 hen transferred to the lumenal domain of the interleukin 2 receptor alpha-chain (Tac protein), the cy

33 s of T-cell activation, such as induction of interleukin 2 receptor alpha-chain expression and cytoki

34 The interleukin-2 receptor alpha (IL-2Ralpha) chain is a com

35 The interleukin-2 receptor alpha (IL-2Ralpha) chain is an es

36 zed anti-Tac (HAT) directed toward CD25, the interleukin-2 receptor alpha (IL-2Ralpha) using a human

37 The lincRNA regulated the expression of interleukin-2 receptor alpha (IL2RA), and we named it th

38 tosis reporter system using a chimera of the interleukin-2 receptor alpha (previously referred to as

39 Levels of soluble interleukin-2 receptor alpha (sIL-2Ralpha) and soluble C

40 ecrosis factor receptor 2 (sTNF-R2), soluble interleukin-2 receptor alpha (sIL-2Ralpha), sCD27, B-cel

41 In contrast, interleukin-2 receptor alpha (Tac) on Chinese hamster ov

42 iggered proliferation and of upregulation of interleukin-2 receptor alpha chain (CD25) molecules, but

43 alphabeta T cells expressing high levels of interleukin-2 receptor alpha chain (IL-2R alpha) and maj

44 The interleukin-2 receptor alpha chain (IL-2Ralpha) is poten

45 ipheral immune activation, including soluble interleukin-2 receptor alpha chain (sCD25) levels, as we

46 measured for soluble KIT (sKIT) and soluble interleukin-2 receptor alpha chain (sCD25), which are kn

47 tracellular and transmembrane domains of the interleukin-2 receptor alpha chain (Tac) and the cytopla

48 ) showed a decrease in the expression of the interleukin-2 receptor alpha chain following PMA stimula

49 manized monoclonal antibody specific for the interleukin-2 receptor alpha chain, was safe and efficac

50 he burst phase by variable expression of the interleukin-2 receptor alpha chain.

51 Of these SNPs, two within the interleukin-2 receptor alpha gene (IL2RA) were strongly

52 I interferon signaling and the interleukin-2/interleukin-2 receptor alpha pathway for the induction o

53 Both the interleukin-2 receptor alpha subunit (Tac) and a chimera

54 ochemical routes by expression of a chimeric interleukin-2 receptor alpha subunit (Tac)-FcepsilonRI g

55 sterase release, gamma interferon secretion, interleukin-2 receptor alpha upregulation) were neverthe

56 t of a CD8-Nef chimera or in a fusion of the interleukin-2 receptor alpha with an 11-amino-acid regio

57 ts chromatin remodelling to the IL-2Ralpha ('interleukin-2 receptor alpha') gene, which is ectopicall

58 express FasL and Fas, but not CD69 or CD25 (interleukin-2 receptor alpha) and eventually die via apo

59 n, soluble interleukin-1 receptor I, soluble interleukin-2 receptor alpha, and tumor necrosis factor

60 any genes expressed in the thymus, including interleukin-2 receptor alpha, c-myc, and those encoded b

61 IL2RA/CD25, the gene for interleukin-2 receptor alpha, is emerging as a general s

62 IFN-gamma, the interleukin-2 receptor alpha-chain (CD25) and talin, a c

63 Transcriptional induction of the interleukin-2 receptor alpha-chain (IL-2Ralpha) gene is

64 orting signal to the cytoplasmic tail of the interleukin-2 receptor alpha-chain caused significant ba

65 2Mit80, an interval that includes Il2ra (for interleukin 2 receptor, alpha chain), a gene that is kno

66 Soluble interleukin-2 receptor-alpha (IL-2Ralpha) has been repor

67 s in interleukin-7 receptor-alpha (IL7RA*C), interleukin-2 receptor-alpha (IL2RA*T), MGAT1 (IV(A)V(T-

68 1beta, and interleukin-7) as well as soluble interleukin-2 receptor-alpha were significantly elevated

69 ry group, whereas interleukin-1beta, soluble interleukin-2 receptor-alpha, interleukin-4, interleukin

70 d a composite biomarker panel of 4 proteins (interleukin-2-receptor-alpha, tumor-necrosis-factor-rece

71 rease induced monocyte expression of surface interleukin 2 receptors and increased expression of HLA-

72 binds specifically to the alpha chain of the interleukin-2 receptor and may thus reduce the risk of r

73 ody that binds to CD25 (alpha subunit of the interleukin-2 receptor) and modulates interleukin-2 sign

74 nd endothelin-1), T cell activation (soluble interleukin-2 receptors), and collagen synthesis (carbox

75 ion through the T cell antigen receptor, the interleukin-2 receptor, and by stimulation of protein ki

76 tients correlate with interleukin-6, soluble interleukin-2 receptor, and interleukin-10 concentration

77 rsely correlated with interleukin-6, soluble interleukin-2 receptor, and interleukin-10 concentration

78 ell depletion induction, 1635 (32%) received interleukin 2 receptor antagonist (IL2-RA), and 2596 (50

79 recipients in 1999-2016 who received ATG or interleukin-2 receptor antagonist (IL2RA) for induction.

80 recipients in 1999-2016 who received ATG or interleukin-2 receptor antagonist (IL2RA) for induction.

81 hymocyte globulin (r-ATG, n = 688) and human interleukin-2 receptor antagonist (IL2Ra, n = 467).

82 ), high-dose methylprednisolone, and an anti-interleukin-2 receptor antagonist antibody.

83 e clearance was also similar between groups (interleukin-2 receptor antagonist group 56 +/- 20 mL/min

84 e low and similar between groups (10% in the interleukin-2 receptor antagonist group vs 6% in the RAT

85 /plasmapheresis preconditioning regimen with interleukin-2 receptor antagonist induction along with t

86 an 60 min, absence of recipient splenectomy, interleukin-2 receptor antagonist induction, and era.

87 nsplant recipients receive induction with an interleukin-2 receptor antagonist, and basiliximab is th

88 , rabbit antithymocyte globulin (r-ATG), and interleukin-2 receptor-antagonist.

89 364), antithymocyte globulin (ATG; n=4,930), interleukin-2 receptor antagonists (IL-2RA; n=4,378), or

90 The impact of induction (thymoglobulin, interleukin-2 receptor antagonists [IL-2RA], or alemtuzu

91 antithymocyte globulin (RATG) compared with interleukin-2 receptor antagonists in a racially diverse

92 In non-AAs/HLA mismatch (1-6), interleukin-2 receptor antagonists versus RATG (OR 1.40,

93 tandard induction immunosuppression was with interleukin-2 receptor antagonists, and antithymocyte gl

94 A total of 200 patients (n = 98 in the interleukin-2 receptor antagonists, and n = 102 in the R

95 match, rabbit antithymocyte globulin (RATG), interleukin-2 receptor antagonists, tacrolimus (FK), cyc

96 n cells activated in vitro with MTg and anti-interleukin-2 receptor (anti-IL-2R), anti-IL-2, or anti-

97 is more effective than Thymoglobulin or anti-interleukin 2 receptor antibodies cannot be answered at

98 .1%) when compared with those receiving anti-interleukin-2 receptor antibodies (2%) and non-induction

99 splantation outcomes between alemtuzumab and interleukin-2 receptor antibodies (IL-2RA) in living don

100 isk of BPAR compared with induction with the interleukin-2 receptor antibodies (IL-2RAs): basiliximab

101 Different anti-interleukin-2 receptor antibodies are also reviewed as a

102 lso distinguished patients who received anti-interleukin-2 receptor antibodies from those who receive

103 duction agents included T-cell-depleting and interleukin-2 receptor antibodies.

104 galovirus (CMV) infection compared with anti-interleukin 2 receptor antibody (anti-IL-2RA).

105 polyclonal antibody or OKT3 (n = 62, 33.5%), interleukin-2 receptor antibody (n = 61, 33%), and no in

106 unosuppressive protocol consisted of an anti-interleukin-2 receptor antibody for induction, and mycop

107 phenolate mofetil, corticosteroids, and anti-interleukin-2 receptor antibody induction, results in im

108 phenolate mofetil, corticosteroids, and anti-interleukin-2 receptor antibody induction, was associate

109 l as either rabbit antithymocyte globulin or interleukin-2 receptor antibody induction.

110 tely by increased immunosuppression and anti-interleukin-2 receptor antibody.

111 Although the clinical benefit of interleukin-2-receptor antibody (IL-2RAb) induction in r

112 trates the common gamma chain, impairing the interleukin-2 receptor assembly and downstream signallin

113 on the cell surface such as Fas and CD69 and interleukin 2 receptor, at comparable levels as those T

114 Interleukin-2 receptor B (IL-2RB) and IL-2Ry fail to be

115 n of a chimeric cytokine receptor (the mouse interleukin 2 receptor beta chain [IL-2Rbeta] extracellu

116 n a lymphopenic host upregulate CD44, CD122 (interleukin 2 receptor beta) and Ly6C expression, acquir

117 ignaling and their maturation depends on the interleukin 2 receptor beta-chain.

118 be relevant in vivo, since p12(I) binds the interleukin-2 receptor beta and gammac chains, raising t

119 he EPOR and the extracellular domains of the interleukin-2 receptor beta and gammac chains.

120 sion of the antiapoptotic molecule Bcl-2 and interleukin-2 receptor beta chain and diminished IL-15-d

121 s are indistinguishable, except for enhanced interleukin 2 receptor-beta (IL-2Rbeta) and suppressed i

122 IL-2 signals via interleukin-2 receptor-beta (IL-2Rbeta):IL-2Rgamma heter

123 However, an interleukin-2 receptor-beta1D chimera containing the cyt

124 e-1 diabetes, baseline femoral neck T-score, interleukin-2 receptor blockade, and proteinuria (HR 2.0

125 tandard immunosuppression with Thymoglobulin/interleukin 2 receptor blocker and mycophenolate mofetil

126 Daclizumab, a highly humanized, specific interleukin-2 receptor blocker, may be efficacious to th

127 tion treatments (alemtuzumab, thymoglobulin, interleukin-2 receptor blockers, and no induction) given

128 nt reports have demonstrated the efficacy of interleukin-2-receptor blockers in lowering the incidenc

129 lung transplant subjects also expressed the interleukin-2 receptor, but only during the early post-t

130 body directed against the alpha-chain of the interleukin 2 receptor (CD25), has been extensively eval

131 dy directed against the alpha chain of human interleukin-2 receptor (CD25), reduces the incidence of

132 disorders expressing Tac (alpha chain of the interleukin 2 receptor; CD25), physiologic shedding of t

133 organ-based disease, serum levels of soluble interleukin-2 receptor, collagen propeptides (N propepti

134 Additional knockout of interleukin 2 receptor common gamma chain (IL-2Rgammac)

135 ed, SIN lentiviral vector encoding the human interleukin 2 receptor common gamma chain (IL2RG) gene a

136 ntibodies against CD4 and alpha-chain of the interleukin-2 receptor complex (CD25).

137 a humanized monoclonal antibody recognizing interleukin-2 receptor (daclizumab), which has proven to

138 onal antibodies that block the high-affinity interleukin-2 receptor expressed on alloantigen-reactive

139 e CD4:CD8 inversion, and marked reduction in interleukin-2 receptor expression by CD4(+) T cells.

140 In contrast, CD25 (alpha chain of interleukin-2 receptor) expression did not differ.

141 composed of Tac antigen, the alpha-chain of interleukin 2-receptor, fused to the first five amino ac

142 odeficiency (SCID-X1) caused by mutations in interleukin 2 receptor gamma (IL2RG) gene threatens the

143 nterferon, CCL5, CXCL1, CXCL2, CXCL7, CXCL9, interleukin 2 receptor gamma (IL2Rgamma), IL21R, CCR2, a

144 letely abolished in interleukin 33 (IL-33)-, interleukin 2 receptor gamma chain (IL2ry)-, and interle

145 ransplantation into immunodeficient NOD/SCID/interleukin 2 receptor gamma chain null mice.

146 ), Recombination Activating Gene (Rag)-2 and Interleukin-2 Receptor Gamma (Il2rg) genes were inactiva

147 is due to mutations in the gene encoding the Interleukin-2 receptor gamma chain (IL-2Rgamma), leading

148 of iCD8alpha cells depends on expression of interleukin-2 receptor gamma chain (IL-2Rgammac), IL-15,

149 se of more highly immunocompromised NOD/SCID interleukin-2 receptor gamma chain null (Il2rg(-/-)) mic

150 nicity studies in immunocompromised NOD/SCID interleukin-2 receptor gamma chain null (NSG), immunocom

151 rus-based gamma-retrovirus vector expressing interleukin-2 receptor gamma-chain (gammac) complementar

152 se diabetic/severe combined immunodeficiency/interleukin-2 receptor-gamma-null (NOD-SCID IL2Rgamma(nu

153 se diabetic/severe combined immunodeficiency/interleukin-2 receptor-gamma-null (NSgamma) mice with li

154 brane domain of the Tac subunit of the human interleukin 2 receptor (gp55) fused to the cytoplasmic d

155 body directed against the alpha chain of the interleukin 2 receptor, has been shown to reduce the inc

156 genitors by augmenting responsiveness of the interleukin 2 receptor (IL-2R) and transcription factor

157 or (TfR) expression follows the induction of interleukin 2 receptor (IL-2R) expression in a sequence

158 The interleukin 2 receptor (IL-2R) generates proliferative s

159 Signaling through the interleukin 2 receptor (IL-2R) involves phosphorylation

160 ells), which have abundant expression of the interleukin 2 receptor (IL-2R), are reliant on IL-2 prod

161 of alpha, beta, and gamma(c) subunits of the interleukin 2 receptors (IL-2R) in plasma membranes of K

162 f the erythropoietin receptor (EPO-R) or the interleukin-2 receptor (IL-2-R) by their respective liga

163 Interleukin-2 receptor (IL-2R alpha) expression was, how

164 ody that recognizes the alpha subunit of the interleukin-2 receptor (IL-2R alpha).

165 was associated with a specific deficiency of interleukin-2 receptor (IL-2R) alpha-chain up-regulation

166 expressed activation markers, as measured by interleukin-2 receptor (IL-2R) and transcription factor

167 immunostaining with DEC-205, B7-1, CD4, and interleukin-2 receptor (IL-2R) antibodies and histopatho

168 Here we identify human interleukin-2 receptor (IL-2R) beta chain (IL2RB) gene d

169 12(I) binds to the cytoplasmic domain of the interleukin-2 receptor (IL-2R) beta chain that is involv

170 and degradation of the interleukin-2 (IL-2)-interleukin-2 receptor (IL-2R) complex.

171 s are capable of up-regulating high-affinity interleukin-2 receptor (IL-2R) expression.

172 In hematopoietic cells, interleukin-2 receptor (IL-2R) gamma chain (termed gamma

173 STAT5 transcription factor downstream of the Interleukin-2 receptor (IL-2R) induces expression of Fox

174 The interleukin-2 receptor (IL-2R) is composed of one affini

175 (SRL) in combination with chimeric (c-) anti-interleukin-2 receptor (IL-2R) monoclonal antibodies (mA

176 vel was independent of that from circulating interleukin-2 receptor (IL-2R) or IL-8 levels.

177 lerance and anti-inflammatory responses, and interleukin-2 receptor (IL-2R) signaling is critical for

178 Interleukin-2 receptor (IL-2R) signaling is essential fo

179 Interleukin-2 receptor (IL-2R) signaling regulates toler

180 IgG1 directed against the alpha chain of the interleukin-2 receptor (IL-2R), is a competitive inhibit

181 cts with the beta and gamma(c) chains of the interleukin-2 receptor (IL-2R), the heavy chain of the m

182 to both the beta and gamma(c) chains of the interleukin-2 receptor (IL-2R).

183 umber of primitive thymocytes expressing the interleukin-2 receptor (IL-2R, CD25).

184 The alpha subunit of the interleukin-2 receptor (IL-2Ralpha) is a cell-surface re

185 n the expression of the alpha subunit of the interleukin-2 receptor (IL-2Ralpha) was examined.

186 ntibody that binds to the alpha chain of the interleukin-2 receptor (IL-2Ralpha), administered for a

187 pansion of alloreactive donor T cells, their interleukin-2-receptor (IL-2R) alpha-chain expression an

188 ells, fewer CD4+ cells, and more activated ([interleukin-2 receptor+], IL-2R+) CD8+ T cells.

189 The interleukin 2 receptor (IL2R) plays a prominent role in

190 mmon cytokine receptor gamma chain (NOD/SCID/interleukin 2 receptor [IL2r] gamma(null)) efficiently s

191 dy directed against the alpha subunit of the interleukin 2 receptor, in reducing acute rejection afte

192 IL2RG, which encodes the gamma-chain of the interleukin-2 receptor, in a mouse model of the disease

193 rothrombin activity, urea, white blood cell, interleukin-2 receptor, indirect bilirubin, myoglobin, a

194 Multivariate analyses identified interleukin-2-receptor induction with daclizumab versus

195 pid withdrawal of prednisone using Simulect (interleukin 2 receptor inhibitor) (n=13).

196 Conversely, interleukin-2 receptor, interferon-gamma, and tumor necr

197 CD25, the alpha chain of the interleukin-2 receptor, is expressed in activated T cell

198 ited by the fact that CD25, the low-affinity interleukin-2 receptor, is up-regulated on conventional

199 was distinguished by less T-cell activation (interleukin-2 receptor+), less proliferation (proliferat

200 cells, absolute number of CD8 cells, soluble interleukin-2 receptor level) were sufficient to define

201 Soluble CD8 and soluble interleukin-2 receptor levels were also elevated in chil

202 differences in the cell types or in soluble interleukin-2 receptor levels.

203 d Nf1-deficient T cells, T-cell receptor and interleukin-2 receptor-mediated proliferation of thymocy

204 mes to the more commonly used combination of interleukin-2 receptor monoclonal antibody induction wit

205 inhibitor, cyclosporine A, the chimeric anti-interleukin-2 receptor monoclonal antibody, basiliximab,

206 ocyte polyclonal antibody or basiliximab, an interleukin-2 receptor monoclonal antibody, is most comm

207 Basiliximab (Simulect), a chimeric anti-interleukin-2 receptor monoclonal antibody, reduced the

208 assess whether basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, reduced the

209 We sought to use anti-CD25 (anti-interleukin-2 receptor) monoclonal antibodies in combina

210 NOD-scid interleukin-2 receptor-negative (IL-2Rgamma(-/-)) (NSG)-

211 the absence of downstream events related to interleukin 2 receptor occupancy and/or cell division.

212 and day 4-was selected to block detection of interleukin-2 receptor on 97% of peripheral blood lympho

213 naling through the common gamma chain of the interleukin-2 receptor on T cells.

214 b (Roche Laboratories, Nutley, NJ) block the interleukin-2 receptor on the surface of activated T cel

215 tively, act by binding to the alpha chain of interleukin-2 receptors on activated T lymphocytes.

216 s was observed as well as a disappearance of interleukin 2 receptor-positive cells.

217 es composed of R73-positive T cells and rare interleukin-2 receptor-positive cells, which was not obs

218 3-positive cells and 88% for the presence of interleukin-2 receptor-positive or HLA-DR-positive cells

219 tion of IgG anti-HLA class II antibodies and interleukin-2 receptor--positive T-cell outgrowth from b

220 Transduction was independent of interleukin-2 receptor/raft-, caveolar- and clathrin-med

221 a humanized monoclonal antibody against the interleukin-2 receptor, reduced the risk of rejection wi

222 Levels of serum soluble interleukin 2 receptor (sIL-2R) provide a reliable marke

223 To compare the value of soluble interleukin 2 receptor (sIL-2R) with ACE as diagnostic b

224 Reductions in serum interleukin-2 receptor (sIL-2R) levels correlated with r

225 The soluble interleukin-2 receptor (sIL-2R, sIL2R, sTAC, sCD25) is a

226 1) and sinks for proinflammatory cytokines (interleukin-2 receptor subunit CD25).

227 r-like effector nucleases (TALENs) to target interleukin-2 receptor subunit gamma (IL2RG) in pronucle

228 pathogenic germline mutation in the X-linked interleukin-2 receptor subunit gamma gene (IL2RG), which

229 as fused to the gpI transmembrane domain and interleukin-2 receptor (tac) ectodomain.

230 f a model PM protein, the alpha chain of the interleukin-2 receptor (Tac).

231 s enzyme provides a crucial link between the interleukin-2 receptor, the protooncogene PKB, and p70 S

232 otein containing the ectodomain of the human interleukin-2 receptor to the TGN.

233 ride, interleukin-6, interleukin-10, soluble interleukin-2 receptor, tumor necrosis factor-alpha, and

234 tive cells expressing the alpha chain of the interleukin 2 receptor) were removed by immunomagnetic s

235 ab fragments, which are directed against the interleukin-2 receptor, with glycolate.